Cargando…
A meta-analysis of intravenous thrombolysis versus bridging therapy for ischemic stroke
The purpose of this study was to perform a pooled analysis of randomized controlled trials (RCT) of intravenous thrombolysis (IVT) versus bridging therapy of intravenous thrombolysis and mechanical thrombectomy (IVMT), comparing the efficacy and safety of the two in patients with acute ischemic stro...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524994/ https://www.ncbi.nlm.nih.gov/pubmed/36181087 http://dx.doi.org/10.1097/MD.0000000000030879 |
_version_ | 1784800611965861888 |
---|---|
author | Wang, Raoqiong Li, Shuangyang Hao, Linyao Wang, Zhichuan Ge, Zhengxin Yang, Sijin |
author_facet | Wang, Raoqiong Li, Shuangyang Hao, Linyao Wang, Zhichuan Ge, Zhengxin Yang, Sijin |
author_sort | Wang, Raoqiong |
collection | PubMed |
description | The purpose of this study was to perform a pooled analysis of randomized controlled trials (RCT) of intravenous thrombolysis (IVT) versus bridging therapy of intravenous thrombolysis and mechanical thrombectomy (IVMT), comparing the efficacy and safety of the two in patients with acute ischemic stroke (AIS). METHODS: All eligible RCT articles from database establishment to December 8, 2021 were searched in databases such as PubMed, Ovid, Embase, Web of science, Cochrane Library, etc. Efficacy outcomes were assessed by modified RANKIN scal (mRS) score, complete recanalization or reperfusion (TICI), National Institute of Health Stroke Scal (NIHSS) score, 90-day mortality, 24 to 36 h incidence of symptomatic intracranial hemorrhage (sICH). RESULTS: Our study included 6 RCT involving 1717 patients. The proportion of the primary efficacy outcome (mRS score 0‐2 at 90 days) was significantly different between IVT and IVMT (OR 0.51; 95% CI 0.35‐0.76). For the secondary efficacy outcome, the study found a significant difference in the proportion of TICI (pooled OR was 0.055, 95% CI 0.07‐0.33). There was a significant difference in the 24 h NIHSS score between the IVT group and the IVMT group (pooled MD was 3.25, 95% CI 0.80‐5.70). There were no significant differences in the NIHSS score at 90 days, the death rate at 90 days, and the sICH at 24 to 36 hours between the two groups. CONCLUSIONS: This study confirms that IVMT is more effective and safe than IVT alone in patients with AIS. However, more and higher-quality randomized clinical trials comparing IVMT to IV alone are warranted for validation. |
format | Online Article Text |
id | pubmed-9524994 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-95249942022-10-03 A meta-analysis of intravenous thrombolysis versus bridging therapy for ischemic stroke Wang, Raoqiong Li, Shuangyang Hao, Linyao Wang, Zhichuan Ge, Zhengxin Yang, Sijin Medicine (Baltimore) Research Article The purpose of this study was to perform a pooled analysis of randomized controlled trials (RCT) of intravenous thrombolysis (IVT) versus bridging therapy of intravenous thrombolysis and mechanical thrombectomy (IVMT), comparing the efficacy and safety of the two in patients with acute ischemic stroke (AIS). METHODS: All eligible RCT articles from database establishment to December 8, 2021 were searched in databases such as PubMed, Ovid, Embase, Web of science, Cochrane Library, etc. Efficacy outcomes were assessed by modified RANKIN scal (mRS) score, complete recanalization or reperfusion (TICI), National Institute of Health Stroke Scal (NIHSS) score, 90-day mortality, 24 to 36 h incidence of symptomatic intracranial hemorrhage (sICH). RESULTS: Our study included 6 RCT involving 1717 patients. The proportion of the primary efficacy outcome (mRS score 0‐2 at 90 days) was significantly different between IVT and IVMT (OR 0.51; 95% CI 0.35‐0.76). For the secondary efficacy outcome, the study found a significant difference in the proportion of TICI (pooled OR was 0.055, 95% CI 0.07‐0.33). There was a significant difference in the 24 h NIHSS score between the IVT group and the IVMT group (pooled MD was 3.25, 95% CI 0.80‐5.70). There were no significant differences in the NIHSS score at 90 days, the death rate at 90 days, and the sICH at 24 to 36 hours between the two groups. CONCLUSIONS: This study confirms that IVMT is more effective and safe than IVT alone in patients with AIS. However, more and higher-quality randomized clinical trials comparing IVMT to IV alone are warranted for validation. Lippincott Williams & Wilkins 2022-09-30 /pmc/articles/PMC9524994/ /pubmed/36181087 http://dx.doi.org/10.1097/MD.0000000000030879 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Wang, Raoqiong Li, Shuangyang Hao, Linyao Wang, Zhichuan Ge, Zhengxin Yang, Sijin A meta-analysis of intravenous thrombolysis versus bridging therapy for ischemic stroke |
title | A meta-analysis of intravenous thrombolysis versus bridging therapy for ischemic stroke |
title_full | A meta-analysis of intravenous thrombolysis versus bridging therapy for ischemic stroke |
title_fullStr | A meta-analysis of intravenous thrombolysis versus bridging therapy for ischemic stroke |
title_full_unstemmed | A meta-analysis of intravenous thrombolysis versus bridging therapy for ischemic stroke |
title_short | A meta-analysis of intravenous thrombolysis versus bridging therapy for ischemic stroke |
title_sort | meta-analysis of intravenous thrombolysis versus bridging therapy for ischemic stroke |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524994/ https://www.ncbi.nlm.nih.gov/pubmed/36181087 http://dx.doi.org/10.1097/MD.0000000000030879 |
work_keys_str_mv | AT wangraoqiong ametaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke AT lishuangyang ametaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke AT haolinyao ametaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke AT wangzhichuan ametaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke AT gezhengxin ametaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke AT yangsijin ametaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke AT wangraoqiong metaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke AT lishuangyang metaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke AT haolinyao metaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke AT wangzhichuan metaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke AT gezhengxin metaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke AT yangsijin metaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke |